Cognitive Limits, Herding Effects, and Group Segregation: Stigma Generation and Destigmatization Pathways of Hepatitis B Patients in China

Author:

Wan Siyu,Xu Junling,Xue Muhan

Abstract

Hepatitis B, once the number one epidemic in China, afflicted nearly 300 million Chinese people. Today, it is still the number one killer of infectious diseases. Due to the strong pathogenicity of hepatitis B, many people in mainland China are scared of the disease. They are afraid to avoid it, leaving many hepatitis B patients and even carriers to suffer much discrimination. They are typically denied the right to work, live and marry because of hepatitis B. As a result, many people with hepatitis B and those who are carriers of the virus suffer from stigma. In this paper, the authors analyze data on hepatitis B patients and pages, as well as data published by the Chinese Ministry of Health on hepatitis B, to connect the dots between the daily lives of hepatitis B patients and the discrimination they face in China. This will help researchers and the general public to understand hepatitis B and to reduce or even eliminate the fear of hepatitis B. Nowadays; the Chinese government has begun to help the general public understand and eradicate the fear of hepatitis B through health legislation, daily publicity, and education, to give these people a fair and just environment to live in.

Publisher

Darcy & Roy Press Co. Ltd.

Reference20 articles.

1. Alavian, S. M., Fallahian, F, & BagheriLankarani, K. The changing epidemiology of viral hepatitis B in Iran. Journal of Gastrointestinal Liver Diseases, 2007, (16): 403-440.

2. World Health Organization. HIV/AIDS fact sheet. Accessed May 14, 2018, Available from: http://www.who.int/news-room/fact-sheets/detail/hiv-aids.

3. Wang Fuzhen, Zhen Hui&Sun Xiaojin. .Achievements and Prospects of Control of Hepatitis B in China.China's Vaccines and Immunization, 2019, (5): 487-492.

4. Ye Junying, Xie Jianyu&Tan Yixiang..Analysis of Hepatitis B Virus Infection Status of 1220 Pregnant Women in Chongqing City.International Journal of Laboratory Medicine.2006, (7): 666-668.

5. Zhang Zhongqin&Gu Tingting.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. World Journal of Infection, 2006, (4): 396-396.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3